Strong 2H’20 financial results driven by 27% sales growth and a 15% reduction in net loss compared to prior year period The Company...
Mauna Kea Technologies announces today the establishment of an equity financing facility with Kepler Cheuvreux acting as financial intermediary...
Company to host business update conference call on Thursday, April 22, 2021, at 6:00 PM CEST (Paris time) / 12:00 noon (New York time) Mauna...
Evaluating the Role of Cellvizio to Measure Acute and Long-Term Pulmonary Impairment Mauna Kea Technologies is supporting research to...
Further peer-reviewed clinical evidence demonstrates Cellvizio enhances diagnostic accuracy and patient management including surgical...
We are excited to announce the launch of the New Cellvizio application for iOS and Android. We hope it will be a useful resource for you in getting...
Fourth quarter total sales increased 41% year-over-year; U.S. sales up 44% Full year sales decreased 12% year-over-year; U.S. sales up...
READ THE COMPLETE PRESS RELEASE
Preliminary Fourth Quarter Total Sales Increase 30% to 36% year-over-year; U.S. Sales up 34% to 38% year-over-year and up 20% to 23%...
Mauna Kea Technologies today announced that management will participate in the following upcoming investor conferences in January: The...
Mauna Kea Technologies announced today the cooptation by the Board of Ms. Jacquelien ten Dam as an Independent Director, effective immediately....
The IRiS Alliance is an exclusive scientific and clinical research collaboration that combines two highly complementary technologies to deliver...
